Background: In 2025, the American Medical Association revised Current Procedural Terminology (CPT) codes for intra-abdominal tumor resections, replacing the >10 cm category with three new categories: 10.1–20 cm, 20.1–30 cm, and >30 cm. We hypothesized these codes would better reflect case complexity and improve alignment between operative burden and reimbursement. Study Design: This retrospective cohort study used the National Cancer Database (2004-2022) to identify adult patients who underwent retroperitoneal sarcoma resection. Patients were classified using old and revised CPT codes, with a 20 cm threshold identifying tumors eligible for re-coding. Anticipated changes in work relative value units (wRVU) were calculated using weighted averages. Logistic regression assessed annual trends in tumors >20 cm. Paired t-tests and chi-square tests compared demographics and proportions of sarcomas >20 cm resected across clinical settings. Results: Of 12,940 patients, 72.1% (n = 9,326) fell under the >10 cm category per old guidelines. With 2025 revisions, 37% (n = 4,789) qualified for different CPT codes due to tumors >20 cm, leading to an expected 30.4% relative increase (30.1 to 39.3) in average wRVU. Most sarcomas >20 cm were resected at Academic/Research Programs (62.7%, p 20 cm were typically insured privately (45.8%) or by Medicare (40.6%) without significant differences in insurance types between 10-20 cm and >20 cm groups ( p = 0.4). Conclusion: Revised CPT codes better capture the heterogeneity and surgical complexity of retroperitoneal sarcomas. These changes will likely have the greatest impact in academic settings, with implications for all insurers.
Simons et al. (Tue,) studied this question.